title: Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
abstract: OBJECTIVE
  A phase II study was performed to investigate the safety and efficacy of concurrent chemoradiotherapy (CCRT) combined with an orally active fluoropyrimidine, S-1, plus cisplatin for locally advanced esophageal cancer (LAEC).
  
  
  METHODS
  CCRT comprised 2 courses, a 30-Gy radiotherapy over 3 weeks plus daily oral S-1 (80 mg/m(2)/day) for 2 weeks and a 24-hour cisplatin infusion (70 mg/m(2)) on day 8, and an identical course administered after a 2-week break.
  
  
  RESULTS
  One hundred and sixteen patients, 12 with stage II, 71 with stage III, and 33 with stage IVa LAEC participated, and 106 of them (91.4%) completed the CCRT course. The most serious toxicity was myelosuppression: grade 3 and 4 neutropenia occurred in 28.4 and 9.5% of patients, respectively. Nonhematologic toxicity was moderate. Complete response rates in patients with stage II, III, and IVa LAEC were 91.7, 67.6, and 36.4%, respectively. The overall median survival time was 2.3 years and that of patients with stage II, III, and IVa cancer was 7.0, 2.6, and 1.3 years, respectively.
  
  
  CONCLUSIONS
  CCRT combined with S-1 plus cisplatin showed promising safety and efficacy. Potentially, this combination therapy could become a baseline medication for patients with LAEC.
authors.affiliation: Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan. iwaseh @ nnh.hosp.go.jp
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Iwase
authors.forename: Masaaki
authors.initials: M
authors.lastname: Shimada
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Tsuzuki
authors.forename: Noboru
authors.initials: N
authors.lastname: Hirashima
authors.forename: Masayuki
authors.initials: M
authors.lastname: Okeya
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Hibino
authors.forename: Nobumitsu
authors.initials: N
authors.lastname: Ryuge
authors.forename: Misaki
authors.initials: M
authors.lastname: Yokoi
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kida
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kuno
authors.forename: Yusaku
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Bunichiro
authors.initials: B
authors.lastname: Kato
authors.forename: Masaya
authors.initials: M
authors.lastname: Esaki
authors.forename: Noboru
authors.initials: N
authors.lastname: Urata
authors.forename: Eriko
authors.initials: E
authors.lastname: Kato
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D004338:Drug Combinations; D004938:Esophageal Neoplasms / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D010094:Oxonic Acid / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin